EAN 2022 | The potential of sNfL as an exploratory endpoint for MS trials

Jens Kuhle, MD, PhD, University Hospital Basel, Basel, Switzerland, debates the suitability of serum neurofilament light (sNfL) as an endpoint for studies of multiple sclerosis (MS) disease-modifying therapies. NfL is strongly driven by focal inflammation but remains modestly raised in the progressive disease state. Discerning disease signals from age-related changes in the progressive setting becomes more challenging. Therefore, it is essential to use the reference ranges with age-adjusted and BMI-adjusted sNfL concentrations. Additionally, measures such as glial fibrillary acidic protein (GFAP) will facilitate future trials and speed the development of new MS treatments, especially for progressive disease. This interview took place at the European Academy of Neurology (EAN) 2022 Congress in Vienna, Austria.